FDA Accepts Biologics License Application for Bevacizumab Biosimilar

Samsung Bioepis announced that the FDA accepted a biologics license application for SB8, a biosimilar candidate for bevacizumab.

Source: CancerNetwork - November 21, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news